Soteria Biotherapeutics

Soteria Biotherapeutics

Soteria Biotherapeutics is a biotechnology company developing cancer immunotherapies.

Soteria Biotherapeutics is a biotechnology company developing cancer immunotherapies that is headquartered in San Francisco, California and was founded in 2018 by Alexander Martinko and Zachary Hill.

Soteria Biotherapeutics is developing t-cells that are conditioned to engage antibodies to treat solid tumor cancers. Their platform T-LITETM, offers small molecule-dependent activation of bispecific antibody therapies. The platform is designed to enable treatments through pulsatile activity, and reduce side effects.

The platform incorporates a small molecule-controlled switch to carry out its use and T-cell cytotoxic activity. The platform creates the activity of immunomodulatory therapeutics such as bi-specific T-Cell engagers, and CAR T-cells. Soteria Biotherapeutics offers services in order to develop their protein switches.

Timeline

2018
Soteria Biotherapeutics was founded.

SBA Awards

SBA Award
Agency
Award Type
Amount (USD)
Date Awarded
Soteria Biotherapeutics, Inc. SBIR Phase I Award, April 2019
SBIR
299,600
April 1, 2019
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Alexander Martinko

Co-Founder

Zachary Hill

Co-Founder

Further reading

Title
Author
Link
Type
Date

Soteria Biotherapeutics Company Profile: Valuation & Investors | PitchBook

Web

Soteria Biotherapeutics Company Profile: Valuation & Investors | PitchBook

Web

Documentaries, videos and podcasts

Title
Date
Link

Soteria Therapeutics Pitch Example | UCSF Entrepreneurship Center Startup 101

May 15, 2018

Companies

Company
CEO
Location
Products/Services

Soteria Biotherapeutics

San Francisco, California, United States

Biotherapeutics

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.